PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?

PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?

Show other versions (1)

The steady increase in the prevalence of allergic diseases causes the social significance of this pathology. These statistics often do not reflect the true morbidity picture. The social and economic burden of allergy forces experts to seek new ways of preventing the beginnings and development of thi...

Full description

Bibliographic Details
Main Authors: E.A. Vishneva, L.S. Namazova-Baranova, R.M. Torshkhoeva, T.V. Kulichenko, A.Yu. Tomilova, A.A. Alekseeva, T.V. Turti
Format: Article
Language:English
Published: Paediatrician Publishers, LLC 2011-06-01
Series:Pediatričeskaâ Farmakologiâ
Online Access:https://www.pedpharma.ru/jour/article/view/1267
id doaj-a8f2e0188fea49b987fa620ca96ab31b
record_format Article
spelling doaj-a8f2e0188fea49b987fa620ca96ab31b2021-07-28T16:32:37ZengPaediatrician Publishers, LLCPediatričeskaâ Farmakologiâ1727-57762500-30892011-06-018324301262PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?E.A. Vishneva0L.S. Namazova-Baranova1R.M. Torshkhoeva2T.V. Kulichenko3A.Yu. Tomilova4A.A. Alekseeva5T.V. Turti6Scientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow I.M. Sechenov First Moscow State UniversityScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowThe steady increase in the prevalence of allergic diseases causes the social significance of this pathology. These statistics often do not reflect the true morbidity picture. The social and economic burden of allergy forces experts to seek new ways of preventing the beginnings and development of this pathology. The relationship between bronchiolitis caused by respiratory syncytial virus (RSV) infection in the early childhood and further development of asthma was proved by numerous randomized trials. The use of the drug for RSV monoclonal antibodies will reduce not only the incidence of the infection, prevent the development of bronchiolitis, but reduce the risk of asthma in early childhood.Key words: asthma, children, respiratory syncytial virus, prophylaxis.https://www.pedpharma.ru/jour/article/view/1267
collection DOAJ
language English
format Article
sources DOAJ
author E.A. Vishneva
L.S. Namazova-Baranova
R.M. Torshkhoeva
T.V. Kulichenko
A.Yu. Tomilova
A.A. Alekseeva
T.V. Turti
spellingShingle E.A. Vishneva
L.S. Namazova-Baranova
R.M. Torshkhoeva
T.V. Kulichenko
A.Yu. Tomilova
A.A. Alekseeva
T.V. Turti
PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?
Pediatričeskaâ Farmakologiâ
author_facet E.A. Vishneva
L.S. Namazova-Baranova
R.M. Torshkhoeva
T.V. Kulichenko
A.Yu. Tomilova
A.A. Alekseeva
T.V. Turti
author_sort E.A. Vishneva
title PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?
title_short PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?
title_full PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?
title_fullStr PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?
title_full_unstemmed PALIVIZUMAB: NEW OPPORTUNITIES FOR THE ASTHMA PREVENTION?
title_sort palivizumab: new opportunities for the asthma prevention?
publisher Paediatrician Publishers, LLC
series Pediatričeskaâ Farmakologiâ
issn 1727-5776
2500-3089
publishDate 2011-06-01
description The steady increase in the prevalence of allergic diseases causes the social significance of this pathology. These statistics often do not reflect the true morbidity picture. The social and economic burden of allergy forces experts to seek new ways of preventing the beginnings and development of this pathology. The relationship between bronchiolitis caused by respiratory syncytial virus (RSV) infection in the early childhood and further development of asthma was proved by numerous randomized trials. The use of the drug for RSV monoclonal antibodies will reduce not only the incidence of the infection, prevent the development of bronchiolitis, but reduce the risk of asthma in early childhood.Key words: asthma, children, respiratory syncytial virus, prophylaxis.
url https://www.pedpharma.ru/jour/article/view/1267
work_keys_str_mv AT eavishneva palivizumabnewopportunitiesfortheasthmaprevention
AT lsnamazovabaranova palivizumabnewopportunitiesfortheasthmaprevention
AT rmtorshkhoeva palivizumabnewopportunitiesfortheasthmaprevention
AT tvkulichenko palivizumabnewopportunitiesfortheasthmaprevention
AT ayutomilova palivizumabnewopportunitiesfortheasthmaprevention
AT aaalekseeva palivizumabnewopportunitiesfortheasthmaprevention
AT tvturti palivizumabnewopportunitiesfortheasthmaprevention
_version_ 1721265648049324032

Similar Items